Regulatory aspects of integration of pharmacogenetics into drug development

被引：0

|

作者：

Shah R.R. ^{[1
]}

机构：

[1] Pharmacogenetics Working party, Regulatory Sub-group

来源：

International Journal of Pharmaceutical Medicine | 2001年 / 15卷 / 2期

关键词：

Debrisoquine; Narrow Therapeutic Index; CYP2D6 Activity; Drug Development Programme; Metabolic Elimination;

D O I：

10.1097/00124363-200104000-00007

中图分类号：

学科分类号：

摘要：

[No abstract available]

引用

收藏

页码：67 / 69

页数：2

相关论文

共 50 条

[21] Pharmacogenetics and pharmacogenomics in drug discovery and development: An overview
Lindpaintner, K
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2003, 41 (04) : 398 - 410
[22] Pharmacogenetics in drug discovery and development: a translational perspective
Allen D. Roses
Nature Reviews Drug Discovery, 2008, 7 : 807 - 817
[23] Pharmacogenetics: implications for drug development, patients and society
McCarthy, A
NEW GENETICS AND SOCIETY, 2000, 19 (02) : 135 - 143
[24] Pharmacogenetics in drug discovery and development: a translational perspective
Roses, Allen D.
NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (10) : 807 - 817
[25] Pharmacogenetics/-genomics: implications for drug discovery and development
Falk, P
CEPHALALGIA, 2005, 25 (10) : 840 - 840
[26] Trial Geography, Pharmacogenetics, and Global Drug Development
Schuck, R. N.
Florian, J.
Charlab, R.
Pacanowski, M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (03) : 218 - 220
[27] Regulatory aspects of drug dissolution testing
Csóka, I
Paál, TL
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 25 : S223 - S224
[28] DRUG-INTERACTIONS - REGULATORY ASPECTS
SAINTSALVI, B
THERAPIE, 1995, 50 (03): : 215 - 218
[29] Regulatory options for pharmacogenetics
Melzer, D
Zimmern, RL
Detmer, DE
Ling, T
PHARMACOGENOMICS, 2003, 4 (05) : 527 - 530
[30] Pharmacogenetics: a regulatory perspective
Suvarna, R.
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2008, 60 : A75 - A75

← 1 2 3 4 5 →